Research programme: protein kinase inhibitors - SignalChem Lifesciences

Drug Profile

Research programme: protein kinase inhibitors - SignalChem Lifesciences

Alternative Names: AXL inhibitors - SignalChem Lifesciences; CAIX inhibitors - SignalChem Lifesciences; MELK inhibitors - SignalChem Lifesciences; PKD2 inhibitors - SignalChem Lifesciences; SLC 0211; SLC-0121; SLC-0131; SLC-391; TYRO3 inhibitors - SignalChem Lifesciences

Latest Information Update: 02 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SignalChem Lifesciences
  • Class Anti-inflammatories; Antibodies; Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Carbonic anhydrase inhibitors; Interleukin-1 receptor-associated kinase inhibitors; LRRK2 protein inhibitors; MELK protein inhibitors; NF-kappa B inhibitors; Polycystic kidney disease 2 protein inhibitors; Protein kinase inhibitors; Proto-oncogene protein c-mer inhibitors; Tau tubulin kinase 1 inhibitors; TYRO3 receptor protein tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Alzheimer's disease; Autoimmune disorders; Inflammation; Parkinson's disease
  • No development reported Breast cancer

Most Recent Events

  • 09 Dec 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
  • 27 Oct 2017 Updated pharmacodynamics data from a preclinical study in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
  • 17 Jul 2017 SignalChem LifeSciences plans a phase I trial for SLC 0211 for Cancer in the second quarter of 2017 (SignalChem LifeSciences website, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top